Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$15.25
$15.23
$4.81
$15.37
$753.61M-0.06974,748 shs600 shs
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$17.43
-5.3%
$18.13
$16.10
$42.47
$2.19B0.682.33 million shs3.83 million shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$59.04
-1.4%
$61.69
$43.70
$86.53
$1.88B-1.4445,122 shs31,499 shs
Carlyle Group Inc. stock logo
CG
Carlyle Group
$51.17
+1.0%
$44.31
$33.02
$57.50
$18.48B1.852.63 million shs5.03 million shs
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$21.78
-0.5%
$23.87
$14.97
$26.58
$2.66B0.721.11 million shs2.41 million shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.40
$6.65
$381.02M0.93.58 million shsN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$93.82
-0.6%
$78.39
$14.15
$150.00
$7.99B0.211.26 million shs951,387 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%-1.47%+3.08%-20.30%-54.56%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.00%-2.38%-9.86%-10.84%+29.25%
Carlyle Group Inc. stock logo
CG
Carlyle Group
0.00%+9.20%+14.24%+17.39%+27.45%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%-3.11%-12.49%-10.19%+40.61%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%+42.02%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.00%-0.53%+16.07%+47.77%+548.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.501 of 5 stars
4.31.00.04.42.72.50.6
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.5828 of 5 stars
3.52.00.00.03.80.80.6
Carlyle Group Inc. stock logo
CG
Carlyle Group
4.2577 of 5 stars
2.23.02.52.62.22.51.9
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
4.9201 of 5 stars
3.61.00.03.93.43.33.8
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.6916 of 5 stars
3.10.00.04.70.01.70.6
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.7014 of 5 stars
2.51.00.00.03.12.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00
N/AN/AN/A
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.62
Moderate Buy$40.05129.79% Upside
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
3.00
Buy$96.6763.73% Upside
Carlyle Group Inc. stock logo
CG
Carlyle Group
2.38
Hold$53.003.58% Upside
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.25
Buy$32.8350.75% Upside
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.13
Hold$8.45131.51% Upside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3.00
Buy$101.107.76% Upside

Current Analyst Ratings Breakdown

Latest CPRX, CG, APLS, AERI, BLTE, VRNA, and RVNC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$76.00 ➝ $160.00
6/20/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $138.00
6/18/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$92.00 ➝ $116.00
6/11/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.00
6/11/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$95.00 ➝ $110.00
6/5/2025
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/2/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.00
6/2/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $90.00
5/23/2025
Carlyle Group Inc. stock logo
CG
Carlyle Group
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $49.00
5/22/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$49.00 ➝ $41.00
5/15/2025
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$194.13M3.88N/AN/A($3.32) per share-4.59
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M2.80N/AN/A$1.84 per share9.47
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$4.72 per shareN/A
Carlyle Group Inc. stock logo
CG
Carlyle Group
$5.43B3.41$4.19 per share12.21$17.75 per share2.88
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$491.73M5.40$2.45 per share8.90$6.10 per share3.57
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$42.28M188.90N/AN/A$2.56 per share36.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
-$74.81M-$0.77N/AN/AN/A-17.09%N/A-2.00%N/A
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/30/2025 (Estimated)
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$36.14M-$1.36N/AN/AN/AN/A-32.07%-30.91%8/8/2025 (Estimated)
Carlyle Group Inc. stock logo
CG
Carlyle Group
$1.02B$2.9517.3510.801.1019.00%23.78%6.40%8/4/2025 (Estimated)
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$163.89M$1.5713.8710.230.8936.91%42.45%36.59%8/6/2025 (Estimated)
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$2.00N/A3,127.33N/AN/A-69.65%-28.00%8/6/2025 (Estimated)

Latest CPRX, CG, APLS, AERI, BLTE, VRNA, and RVNC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Carlyle Group Inc. stock logo
CG
Carlyle Group
$0.97$1.14+$0.17$0.35$972.27 million$973.10 million
5/7/2025Q1 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million
4/29/2025Q1 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/AN/A
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Carlyle Group Inc. stock logo
CG
Carlyle Group
$1.402.74%N/A47.46%4 Years
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A

Latest CPRX, CG, APLS, AERI, BLTE, VRNA, and RVNC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Carlyle Group Inc. stock logo
CG
Carlyle Group
quarterly$0.353.3%5/19/20255/19/20255/27/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/A
2.27
1.92
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.76
4.08
3.62
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
24.31
24.31
Carlyle Group Inc. stock logo
CG
Carlyle Group
1.56
2.36
2.36
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
6.14
5.96
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.07
8.86
8.73
CompanyEmployeesShares OutstandingFree FloatOptionable
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
37649.42 million47.22 millionOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770125.68 million117.14 millionOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1031.84 million27.61 millionNot Optionable
Carlyle Group Inc. stock logo
CG
Carlyle Group
2,300361.14 million266.16 millionOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80121.97 million109.29 millionOptionable
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3085.13 million81.05 millionOptionable

Recent News About These Companies

Verona Pharma: An Impressive Initial Launch

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aerie Pharmaceuticals stock logo

Aerie Pharmaceuticals NASDAQ:AERI

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$17.43 -0.97 (-5.27%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$18.25 +0.82 (+4.70%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$59.04 -0.86 (-1.44%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$60.75 +1.71 (+2.90%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Carlyle Group stock logo

Carlyle Group NASDAQ:CG

$51.17 +0.50 (+0.99%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$51.07 -0.10 (-0.20%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Carlyle Group Inc. is an investment firm specializing in direct and fund of fund investments. Within direct investments, it specializes in management-led/ Leveraged buyouts, privatizations, divestitures, strategic minority equity investments, structured credit, global distressed and corporate opportunities, small and middle market, equity private placements, consolidations and buildups, senior debt, mezzanine and leveraged finance, and venture and growth capital financings, seed/startup, early venture, emerging growth, turnaround, mid venture, late venture, PIPES. The firm invests across four segments which include Corporate Private Equity, Real Assets, Global Market Strategies, and Solutions. The firm typically invests in industrial, agribusiness, ecological sector, fintech, airports, parking, Plastics, Rubber, diversified natural resources, minerals, farming, aerospace, defense, automotive, consumer, retail, industrial, infrastructure, energy, power, healthcare, software, software enabled services, semiconductors, communications infrastructure, financial technology, utilities, gaming, systems and related supply chain, electronic systems, systems, oil and gas, processing facilities, power generation assets, technology, systems, real estate, financial services, transportation, business services, telecommunications, media, and logistics sectors. Within the industrial sector, the firm invests in manufacturing, building products, packaging, chemicals, metals and mining, forestry and paper products, and industrial consumables and services. In consumer and retail sectors, it invests in food and beverage, retail, restaurants, consumer products, domestic consumption, consumer services, personal care products, direct marketing, and education. Within aerospace, defense, business services, and government services sectors, it seeks to invest in defense electronics, manufacturing and services, government contracting and services, information technology, distribution companies. In telecommunication and media sectors, it invests in cable TV, directories, publishing, entertainment and content delivery services, wireless infrastructure/services, fixed line networks, satellite services, broadband and Internet, and infrastructure. Within real estate, the firm invests in office, hotel, industrial, retail, for sale residential, student housing, hospitality, multifamily residential, homebuilding and building products, and senior living sectors. The firm seeks to make investments in growing business including those with overleveraged balance sheets. The firm seeks to hold its investments for four to six years. In the healthcare sector, it invests in healthcare services, outsourcing services, companies running clinical trials for pharmaceutical companies, managed care, pharmaceuticals, pharmaceutical related services, healthcare IT, medical, products, and devices. It seeks to invest in companies based in Sub-Saharan focusing on Ghana, Kenya, Mozambique, Botswana, Nigeria, Uganda, West Africa, North Africa and South Africa focusing on Tanzania and Zambia; Asia focusing on Pakistan, India, South East Asia, Indonesia, Philippines, Vietnam, Korea, and Japan; Australia; New Zealand; Europe focusing on France, Italy, Denmark, United Kingdom, Germany, Austria, Belgium, Finland, Iceland, Ireland, Netherlands, Norway, Portugal, Spain, Benelux , Sweden, Switzerland, Hungary, Poland, and Russia; Middle East focusing on Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey, and UAE; North America focusing on United States which further invest in Southeastern United States, Texas, Boston, San Francisco Bay Area and Pacific Northwest; Asia Pacific; Soviet Union, Central-Eastern Europe, and Israel; Nordic region; and South America focusing on Mexico, Argentina, Brazil, Chile, and Peru. The firm seeks to invest in food, financial, and healthcare industries in Western China. In the real estate sector, the firm seeks to invest in various locations across Europe focusing on France and Central Europe, United States, Asia focusing on China, and Latin America. It typically invests between $1 million and $50 million for venture investments and between $50 million and $2 billion for buyouts in companies with enterprise value of between $31.57 million and $1000 million and sales value of $10 million and $500 million. It seeks to invest in companies with market capitalization greater than $50 million and EBITDA between $5 million to $25 million. It prefers to take a majority or a minority stake. While investing in Japan, it does not invest in companies with more than 1,000 employees and prefers companies' worth between $100 million and $150 million. The firm originates, structures, and acts as lead equity investor in the transactions. The Carlyle Group Inc. was founded in 1987 and is based in Washington, District of Columbia with additional offices in 21 countries across 5 continents (North America, South America, Asia, Australia and Europe).

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.78 -0.11 (-0.50%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$22.00 +0.22 (+1.01%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)
As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$93.82 -0.58 (-0.61%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$93.69 -0.13 (-0.14%)
As of 04:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.